about camurus news products technologies partnering contact products Our product pipeline Camurus' development projects address serious unmet medical needs over a range of therapeutic areas, including cancer, endocrinology, pain, metabolic disease and drug addiction. Our product pipeline represents a healthy mix of in-house and partnered projects in different development phases. CAM2029 Neuroendocrine tumors 60% CAM2029 Acromegaly 60% CAM2038 weekly Opioid dependence 60% CAM2038 monthly Opioid dependence 60% CAM2032 (Prosenze®) Prostate cancer 60% CAM2048 Pain 40% Collaborations on partner drugs Undisclosed 40% episil® Oral mucositis 60% episil® Oral mucositis pain episil® oral liquid is a unique local treatment of pain in the oral cavity resulting from inflammation and ulcers in the oral cavity. It has been demonstrated effective in treating e.g. oral mucositis, a severe and sometimes treatment limiting side effect of cancer chemotherapy or radiation. The product is administered as a lipid-based liquid that spreads on the mucosal surface where it transforms into a highly bioadhesive film, thereby protecting the sensitised and sore mucosa. episil® oral liquid is conveniently administered using small pocket sized pump device. › CAM2038 Opioid dependence CAM2038 is a new long-acting buprenorphine product for the stabilization and maintenance treatment of patients dependent on painkiller and illicit opioids. CAM2038 represents a new treatment concept for patients dependent on prescription pain killers and illicit opioids, and includes weekly (q1w) and monthly (q4w) buprenorphine injection products. In addition to relieving the burdens of daily medication, CAM2038 products have been specifically designed for minimizing the risks of abuse, misdirection and pediatric exposure associated with presently marketed daily sublingual tablet and film products. Having successfully finalized Phase 1 and Phase 2 trials, Camurus is now continuing with Phase 3 development with the intent to start pivotal studies 2015. CAM2038 is designed for convenient administration by health care professionals as a small volume subcutaneous injection once weekly (q1w) or once monthly (q4w). This allows adjustment of treatment in accordance with the patients needs and treatment stage, with the overall aim to improve the treatment outcome by increasing compliance and safeguarding against misuse, abuse and drug diversion. Opioid dependence to prescription or illicit drugs is a complex health condition that often requires long-term treatment, including medical treatment and counseling. Over the past decade, opioid dependence has become a worldwide public health challenge. Although opioid dependence is a treatable condition, only a small fraction of those suffering from opioid dependence receive adequate treatment today. In the U.S. alone, nearly five million people reported non-medical use of opioids, and approximately 2.5 million met diagnostic criteria for addiction to heroin and prescription painkillers in 2013. › CAM2029 Growth hormone disorders CAM2029 is a ready-to-use, long-acting octreotide product for treatment of acromegaly, carcinoid tumours and other neuroendocrine tumours, NETs. The product consists of a lipid-based liquid administered subcutaneously as a small volume injection. Once injected the lipid constituents immediately start to self-assemble into the FluidCrystal® gel controlled release matrix and therapeutic plasma levels of octreotide are rapidly reached and maintained over one month. › CAM2032 Prostate cancer CAM2032 (Prosenze®) is a new convenient ready-to-use, long-acting leuprolide formulation in development for long-term treatment of prostate cancer. The product is presented as ready-to-use prefilled syringe containing a lipid-based leuprolide solution. It is administered as a low volume subcutaneous injection that rapidly transforms in situ to the FluidCrystal® controlled release matrix, providing consistent plasma levels over time. CAM2032 has been studies in one single dose Phase 2 trial in patients with prostate cancer and is currently being assessed in a second repeat dose Phase 2 trial versus an active comparator. › › UP Innovative nanoscale therapeutics © 2014 Camurus AB home about camurus news products technologies partnering career press contact This website contains information on products which is targeted to a wide audiences and could contain details or information other wise not accessible or valid in your country. Please be aware that we do not take any responibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your region. legal notice privacy policy sitemap Login